Download presentation
Presentation is loading. Please wait.
Published byIrene Serrano Martínez Modified over 5 years ago
1
Pathophysiologic Targets of Allergic Asthma
3
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
4
Defining Allergic Asthma
5
FDA-Approved Agents for Severe Allergic Asthma Not a One-Size-Fits-All Therapy
6
Clarifying the Allergic Asthma Phenotype
7
Pathophysiology of Allergic Asthma
8
Asthma: A Heterogenous Disease With Multiple Phenotypes
9
Drivers of Allergic Asthma
10
IL-5
11
IL-4
12
IL-13
13
Inflammatory Mechanisms of Allergic Asthma
14
Mast Cells
15
Concluding Remarks
16
Therapeutic Targets for Severe Allergic Asthma
17
FDA-Approved Agents for Severe Allergic Asthma and Their Targets
18
Clinical Implications of TH2 Biomarkers
19
Eosinophil Levels Vary Over Time in Patients With Severe Asthma
20
Baseline Clinical Factors and Blood Eosinophil Count Can Help Identify Patients Who Are Potentially Responsive to Benralizumab
21
Liberty Asthma QUEST: Phase 3 Study of Efficacy of Dupilumab on Inflammatory Biomarkers of Asthma in Patients With/Without Allergic Rhinitis
22
Liberty Asthma QUEST: Phase 3 Study of Efficacy of Dupilumab on Inflammatory Biomarkers of Asthma in Patients With/Without Chronic Rhinosinusitis/Nasal Polyps
23
Baseline Blood Eosinophil Levels and/or Clinical Markers of Asthma Severity Predict Response to Omalizumab in Patients With Allergic Asthma
24
Concluding Remarks
25
Clinical Impact of Targeting Allergic Asthma
26
Severe Allergic Asthma: Links Between Exacerbations and Outcomes
27
Preseasonal Treatment With Omalizumab or ICS Boost in Children to Prevent Asthma Exacerbation in the Fall Season
28
Omalizumab in Pediatric Patients With Allergic Asthma and Allergic Rhinitis
29
PROSPERO: Outcomes After Initiation of Omalizumab in a Real-World Setting
30
PROSPERO: What Did We Learn?
31
Comorbidities in Patients With TH2-Asthma Substantially Increase Risk of Asthma Exacerbations
32
Dupilumab for Adults With Concurrent Asthma, Atopic Dermatitis, and Sinonasal Conditions
33
Liberty Asthma QUEST: Dupilumab for Asthma With Allergic Asthma
34
Mepolizumab for Asthma With Allergic Rhinitis, Chronic Rhinosinusitis, and/or Nasal Polyps
35
Concluding Remarks
36
Abbreviations
37
Abbreviations (cont)
38
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.